Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 4/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358084 | 0.78 | MAPK1 (0.38) | ITKGRM4 | |
| SCHEMBL800343 | 0.77 | CCR1 (0.37) | ITKGRM4CYP1A2CLK2DYRK1A | |
| SCHEMBL3950985 | 0.70 | PDPK1 (0.38) | GRM4CYP1A2DYRK1A | |
| SCHEMBL19258970 | 0.67 | YTHDC1 (0.40) | GRM4 | |
| SCHEMBL19801401 | 0.64 | GRM4 (0.33) | GRM4 | |
| SCHEMBL29606019 | 0.60 | MAPK1 (0.33) | — | |
| SCHEMBL2357126 | 0.60 | JAK2 (0.40) | ITKGRM4 | |
| SCHEMBL6923458 | 0.60 | GRM4 (0.70) | GRM4 | |
| SCHEMBL694204 | 0.60 | NOS3 (0.41) | CYP1A2 | |
| SCHEMBL14906033 | 0.59 | MAPK1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895740-B2 | Pyrazolopyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130053388-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053388-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | MAP3K5, MAP3K2, MAP3K20 | ITK 431/4885GRM4 3473/4885CYP1A2 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.